Assignee
SHANGHAI ESCUGEN BIOTECHNOLOGY CO LTD
CN·1 granted patent·3 pending applications·0 citations·filing 2021–2022
Top patents by PatentIndex Score
4 records- 0154US12435135B2Human CD47-targeting single-domain antibody and use thereofSHANGHAI ESCUGEN BIOTECHNOLOGY CO LTD·Filed 2021·Granted Oct 7, 2025·0 cites·23 claims
- 0248US2025268939A1Chimeric Antigen Receptor Molecule for Specifically Recognizing Baff-R and Application of Chimeric Antigen Receptor MoleculeSHANGHAI ESCUGEN BIOTECHNOLOGY CO LTD·Filed 2022·Application pending·0 cites
- 0341US2023096452A1Claudin 18.2 antibody and use thereofSHANGHAI ESCUGEN BIOTECHNOLOGY CO LTD·Filed 2021·Application pending·0 cites
- 0440US2023312704A1Cldn18.2 antibody and use thereofSHANGHAI ESCUGEN BIOTECHNOLOGY CO LTD·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SHANGHAI ESCUGEN BIOTECHNOLOGY CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →